The Daiichi Sankyo Group leverages the research and development capabilities that have been honed over our years of operating as a drug discovery-oriented company to continually create innovative pharmaceuticals that improve upon current standard of care disease management and thereby develop a business that helps improve patient health. (Please refer to Research & Development.)
To quickly adopt the countless findings created worldwide and to meet various medical needs appropriately, the Daiichi Sankyo Group establishes and fosters the partnerships for new drug discovery and technology through many approaches for expansion of external networks and securement of various innovation sources and promotes to merge a diverse range of perspectives into its drug discovery research efforts. (Please refer to Research & Development>Open Innovation .)
Through our research and development capabilities and partnership engagements, the the Daiichi Sankyo Group aims to help address unmet medical needs pertaining to malaria, tuberculosis, neglected tropical diseases in developing countries, and other diseases for which issues regarding access to healthcare are faced in developed or developing countries such as cancer and other non-communicable diseases and rare diseases. 

Partnership Initiatives

Our scientific knowledge and global network drive us forward in creating innovative drugs through partnerships. 

Participation in the GHIT Fund

We have funded the Global Health Innovative Technology Fund ("GHIT Fund") since its establishment in April 2013. To promote the development of drugs for combating infectious diseases in developing countries, the GHIT Fund was established as a public-private partnership originating in Japan and was supported by the government of Japan, five Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation. We have provided the funding for the third phase starting in April 2023, ongoingly from the first and second phases. The GHIT Fund has contributed to breakthroughs in the development of many innovative product through its investments. Our Group is leveraging the partnership through the GHIT Fund structure to undertake a research project.

 

The Global Health Innovative Technology Fund

Participation in the AMR Action Fund

The emergence and spread of drug-resistant bacteria pose a serious global threat to public health. Without effective countermeasures, antimicrobial resistance (AMR) could cause approximately 10 million deaths annually worldwide by 2050. In response to this urgent issue, the AMR Action Fund was launched in July 2020 to support the clinical development of new antibiotics and help establish a sustainable antibiotics market.
The fund aims to bring two to four new antibiotics to market by 2030 through a total investment of US$1 billion and technical assistance to several small biotechnology companies. As of the end of December 2023, the fund had announced investments in seven companies.
The Daiichi Sankyo Group has contributed US$20 million to the Fund, supporting the development of innovative antibiotics and helping to accelerate global efforts to address the AMR crisis.   

Disclosure of Clinical Trial Information

We, as a sponsor, recognize the significance of properly disclosing clinical trial information and results to a wide range of stakeholders in accordance We recognize that it is important to properly disclose clinical trials as a sponsor to a wide range of stakeholders in accordance with regulations and guidelines of each country and industry association. Accordingly, we practice proactive disclosure. Furthermore, it is also important to share clinical trial data with external researchers to deepen their understanding of medicines and to disseminate scientific knowledge, which will ultimately lead to better medical care for patients.

Disclosure of Clinical Trials